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Abstract: The aim of this study was to develop an intranasal in situ thermo-gelling meloxicam-hu-
man serum albumin (MEL-HSA) nanoparticulate formulation applying poloxamer 407 (P407), 
which can be administered in liquid state into the nostril, and to increase the resistance of the for-
mulation against mucociliary clearance by sol-gel transition on the nasal mucosa, as well as to im-
prove drug absorption. Nanoparticle characterization showed that formulations containing 12–15% 
w/w P407 met the requirements of intranasal administration. The Z-average (in the range of 180–304 
nm), the narrow polydispersity index (PdI, from 0.193 to 0.328), the zeta potential (between −9.4 and 
−7.0 mV) and the hypotonic osmolality (200–278 mOsmol/L) of MEL-HSA nanoparticles predict en-
hanced drug absorption through the nasal mucosa. Based on the rheological, muco-adhesion, drug 
release and permeability studies, the 14% w/w P407 containing formulation (MEL-HSA-P14%) was 
considered as the optimized formulation, which allows enhanced permeability of MEL through 
blood–brain barrier-specific lipid fraction. Cell line studies showed no cell damage after 1-h treat-
ment with MEL-HSA-P14% on RPMI 2650 human endothelial cells’ moreover, enhanced permea-
tion (four-fold) of MEL from MEL-HSA-P14% was observed in comparison to pure MEL. Overall, 
MEL-HSA-P14% can be promising for overcoming the challenges of nasal drug delivery. 
Keywords: quality by design; rapid equilibrium dialysis; muco-adhesion; brain PAMPA; RPMI 
2650 nasal epithelial cell 
 
1. Introduction 
Albumin is a versatile, biodegradable drug carrier for numerous therapeutic agents 
that have poor water solubility, unsatisfying pharmacokinetics with low circulation half-
life, inefficient targetability and even instability in vivo. Strategies for applying albumin 
for drug delivery can be classified broadly into exogenous and in situ binding formula-
tions that utilize covalent attachment, non-covalent association, or encapsulation of the 
drug in the form of albumin-based nanoparticles [1]. 
Neurodegenerative diseases are associated with neuroinflammation. The combina-
tion of albumin with non-steroid anti-inflammatory drugs (NSAID) can be promising in 
therapy, which depends on passing the blood–brain barrier (BBB). NSAIDs can have a 
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protective effect in neurodegenerative diseases through different mechanisms. They can 
depolarize the mitochondria, therefore inhibiting calcium ion uptake, due to the ionizable 
carboxylic group [2,3]. Moreover, inhibition of cyclooxygenase (COX) enzymes can sup-
press glia activity and reduce amyloidosis [4]. COX-2 inhibitor NSAIDs such as meloxi-
cam (MEL) can be advantageous in the treatment of neurodegenerative disorders as they 
have improved anti-amnesic activity through inhibiting lipid peroxidation and acetylcho-
linesterase activity in the brain [2] supplemented by additional antioxidant effect [3], but 
the therapeutic application is limited due to the poor BBB transport [5]. To overcome this 
obstacle, choosing the appropriate carrier system and route of administration has a prom-
inent role [6]. 
Nasal administration can be a suitable means of transport route for that purpose; 
moreover, it has been reported that the initial formation of Alzheimer’s disease begins in 
the entorhinal cortex, a region innervated by the olfactory nerves, then progresses accord-
ing to the corresponding pattern [7]. Due to the high surface area and rich vascularization, 
drugs or drug-delivery systems can be easily absorbed from the nasal cavity; moreover, 
first-pass metabolism is negligible through this administration route, which can be advan-
tageous in terms of preserving pharmacological activity [8–10]. Nano drug delivery sys-
tems (nanoDDSs) are able to transport drugs as cargo, bypassing the BBB through the 
trigeminal and olfactory nerves directly into the brain [11]. Moreover, they support in-
tranasal NSAID administration, due to their poor water solubility at nasal pH (5.3–5.6) 
and low residence time (10–15 min) due to mucociliary clearance [12]. In our previous 
study was demonstrated that MEL-human serum albumin (HSA) nanoparticles could be 
successfully applied for nose-to-brain delivery, with improved in vivo brain targeting ef-
ficacy [13]. 
As mucociliary clearance is a limiting factor in nose-to-brain delivery, the application 
of viscosity enhancers or mucoadhesive polymers can be advantageous by increasing the 
residence time on the nasal mucosa, which supports drug absorption [14–16]. To satisfy 
these requirements formulation of in situ thermo-gelling systems can be efficacious. 
Poloxamer 407 (P407), a triblock copolymer consisting of a hydrophobic residue of poly-
oxy-propylene (POP) between the two hydrophilic units of poly-oxyethylene (POE), can 
be applied for development of in situ thermo-reversible gelling systems, through temper-
ature-controlled micelle forming [17–19]. Thermo-gelling occurs due to hydrophobic in-
teractions between the P407 copolymer chains [20]. By optimization of P407 concentration 
in the formulation, a sol–gel transition can be reached at the temperature of the nasal cav-
ity, while it remains in a liquid state below that temperature during storage and admin-
istration. 
As continuous improvement is part of industrial manufacturing and research pro-
cesses, the quality management of nanocarriers having higher potential, in the case of 
beneficial therapeutic applications and effects, should be of paramount importance. Qual-
ity by Design (QbD) offers a proper methodology based on knowledge and risk assess-
ment, ensuring the quality, safety and efficacy of the desirable nanocarrier [21]. In the case 
of nose-to-brain applicable nanocarriers, many physiological and pharmaceutical aspects 
must be taken into account, which are adapted to the versatile biological and chemical 
aspects of this route. As part of the QbD assessment, a comparison study was performed 
between MEL-HSA and MEL-HSA-P407 formulations to evaluate the change of risk se-
verity during a continuous development process [22]. 
Our aim was to optimize an in situ thermo-gelling MEL-HSA-P407 formulation, 
which can be administered in liquid state into the nostril and to increase resistance of 
formulation against mucociliarly clearance by sol–gel transition on the nasal mucosa, as 
well as to improve drug absorption. 
2. Materials and Methods 
2.1. Materials 




3-carboxamide-1,1-dioxide) was donated by EGIS Pharmaceuticals Plc. (Budapest, Hun-
gary) for research work. Human serum albumin (HSA, lyophilized powder, purity > 97%), 
fluorescein isothiocyanate-labelled HSA (FITC-HSA), Tween 80 (Tween), P407, disodium 
hydrogen phosphate (Na2HPO4), sodium dihydrogen phosphate (NaH2PO4), polar brain 
lipid extract, cholesterol, mucin from porcine stomach (Type III), and all reagents for cell 
line studies were purchased from Sigma Aldrich Co. Ltd. (Budapest, Hungary) if not in-
dicated otherwise. Analytical grade solvents such as methanol, dimethyl sulfoxide 
(DMSO) and dodecane were purchased from Molar Chemicals (Budapest, Hungary). So-
dium hyaluronate (NaHA, Mw = 1400 kDa) was obtained from Gedeon Richter Plc. (Bu-
dapest, Hungary). In all experiments, water was purified by the Millipore Milli-Q® 140 
Gradient Water Purification System. 
2.2. Preparation of In Situ Gelling MEL-HSA Nanoparticle Formulations 
MEL-HSA nanoparticles were produced by applying a modified coacervation 
method (Figure 1) according to the following steps [23]: first, Tween-80 was dispersed in 
4 mL of HCl solution (0.1 M), whereas MEL was dissolved in 4 mL of NaOH solution (0.1 
M) and HSA was dissolved in 8 mL of purified water. Then, the Tween 80 solution was 
added dropwise (0.5 mL/min) to the MEL solution at 4 °C under constant stirring (800 
rpm). Next, this MEL–Tween 80 solution was added dropwise to the HSA solution at 4 °C 
under constant stirring (800 rpm). After complete homogenization, additional HCl was 
added dropwise to adjust pH to 5.6, and as a result the solution became turbid. Then, the 
formulation was incubated for 12 h under constant stirring (800 rpm) to obtain nanopar-
ticle dispersion. P407 in various concentrations (based on preliminary experimental re-
sults 12, 13, 14,15 and 16% w/w) was added to the formulation and kept in a cool place (5 
± 3 °C) overnight until complete hydration and dissolution of the polymer, before further 
investigations. 
 
Figure 1. Preparation of MEL-HSA-P407. 
2.3. QbD-Based Comparative Risk Assessment 
As the in situ thermo-gelling carrier system is part of a continuous development pro-
cess, it needs to be compared to the HSA nanoparticles, validating the product life cycle, 
and therefore ensuring quality. At first, the quality target product profile (QTPP) was de-
termined based on the mandatory requirements of a nose-to-brain applicable nanocarrier. 
The critical quality attributes (CQAs) were also determined as they are physicochemical 
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factors affecting product safety, efficacy and quality. Critical process parameters (CPPs) 
and critical material attributes (CMAs) were not taken into account during the risk assess-
ment process as an extensive optimization of P407 concentration was performed. For the 
identified elements, risk levels were assigned for both the MEL-HSA and MEL-HSA-P407. 
A three-level scale was used to describe the relation between these parameters: each rela-
tion was assigned with a “high” (H), “medium” (M) or “low” (L) attributive. To quantify 
the risk values, LeanQbD® Software (QbD Works LLC, Fremont, CA, USA) was used. As 
the output of this comparative risk assessment, severity scores were compared and eval-
uated to determine the influence of the in situ thermo-gelling carrier system on product 
quality. 
2.4. Optimization of In Situ Thermogelling Carrier System 
2.4.1. Rheological Studies 
The rheological measurements were carried out with a Physica MCR302 rheometer 
(Anton Paar, Graz, Austria). A cone and plate type measuring device with cone angle of 
1° was applied; the diameter of the cone was 25 mm, and the gap height in the middle of 
the cone was 0.046 mm. The gelation temperature was measured while the temperature 
was increased from 20 to 40 °C, using 1 °C/min heating rate. The measurement was per-
formed at a constant frequency of 1.0 rad/min and at a constant strain of 1%. The gelation 
time of the polymer solutions was followed at a constant frequency of 1.0 rad/min and at 
a constant strain of 1% at 37 °C. The samples were stored at 5 ± 1 °C and taken immediately 
before the measurement. Viscoelastic character was determined by frequency sweep tests 
immediately after the gelation measurement, with a strain of 1% at 37 °C. Storage modulus 
(G’), loss modulus (G”) and loss factor were determined over the angular frequency range 
from 0.1 to 100 rad/s. The applied strain value (1%) was in the range of the linear viscoe-
lasticity of the gels. 
2.4.2. Muco-adhesion Measurement 
Muco-adhesion was analyzed by means of tensile tests (TA-XT Plus texture analyzer 
(Metron Kft, Budapest, Hungary)) equipped with a 5-kg load cell. As a simulated mucosal 
membrane, a filter paper (Whatman® qualitative filter paper, Sigma Aldrich Co. Ltd., Bu-
dapest, Hungary) with 25 mm diameter, impregnated with 50 µL of an 8% w/w mucin 
dispersion, was used, prepared with a simulated nasal electrolyte solution (SNES) con-
sisting of 8.77 g/L sodium chloride (NaCl), 2.98 g/L potassium chloride (KCl), 0.59 g/L 
anhydrous calcium chloride (CaCl2) and dissolved in purified water; the pH was adjusted 
to 5.6 with 0.1 M HCl [12]. Five parallel measurements were performed. 20 mg of the sam-
ple was attached to the cylinder probe and placed in contact with the filter paper wetted 
with mucin. A 2500 mN preload was used for 3 min, then the cylinder probe was moved 
upwards to separate the sample from the substrate at a prefixed speed of 2.5 mm/min. The 
maximum detachment force (adhesive force) and the work of adhesion (A, mN/mm) were 
measured, the latter calculated as the area (AUC) under the ‘‘force versus distance’’ curve 
using the Exponent Connect software of the instrument. The formulations were thermo-
stated at 37 °C for 30 min before measurement. As a reference system, 0.5% w/w NaHA 
aqueous solution was applied. 
2.4.3. Characterization of Nanoparticles 
The formulations were characterized according to their average hydrodynamic di-
ameter (Z-average), polydispersity index (PdI) and zeta potential using a Malvern Zeta 
sizer Nano ZS (Malvern Instruments, Worcestershire, UK) at 25 and 35 °C in folded capil-
lary cells. The refractive index was set to 1.72. The pH of formulations was measured ap-
plying a WTW® inoLab® pH 7110 laboratory pH tester (Thermo Fisher Scientific, Buda-
pest, Hungary). The osmolality of formulations was determined by osmometer (Knauer 
Semi-micro Osmometer, Berlin, Germany) based on the freezing point depression 
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method. Each measurement was carried out in triplicate and data are shown as means ± 
SD. The encapsulation efficiency and loading capacity of gel-embedded nanoparticles 
were prepared with a Hermle Z323K high performance refrigerated centrifuge (Hermle 
AG, Gossheim, Germany) at 17.500 rpm, 4 °C for 30 min. The amount of free MEL in the 
supernatant was determined by high performance liquid chromatography (HPLC). En-
capsulation efficiency (EE) and loading capacity (LC) of formulations were calculated ac-
cording to the following equations [24]: 𝐸𝐸 (%)  = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 − 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑝𝑝𝑙𝑖𝑒𝑑 ∙ 100 (1)
𝐿𝐶 (%)  = 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑒𝑑𝑀𝑎𝑠𝑠 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 ∙ 100 (2)
The distribution of FITC labelled HSA-MEL nanoparticles in gel structure was visu-
alized by a Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems GmbH, 
Wetzlar, Germany) and Visitron spinning disk confocal system (Visitron Systems GmbH, 
Puchheim, Germany). The P407 containing formulations and the FITC labelled HSA-MEL 
colloidal solution as reference were dropped onto slides and incubated for 10 min at 35 °C 
for thermo-gelling. Then, slides were excited with a 488 nm Argon laser, and fluorescence 
was detected with a 505 to 570 nm BP filter. 
2.4.4. Rapid Equilibrium Dialysis (RED) 
In order to investigate the in vitro dissolution kinetics and release profile of different 
MEL-HSA-P407 formulations at nasal conditions, the RED Device (Thermo ScientificTM, 
Waltham, MA, USA) was used. A suspension of MEL was prepared in a phosphate buffer 
saline (PBS, pH 5.6) with a nominal concentration of 2 mg/mL as a control for the study. 
Both the control and in situ gelling MEL-HSA formulations were homogenized using an 
Eppendorf MixMate (Thermo ScientificTM, Waltham, MA, USA) vortex mixer for 30 s and 
an ultrasonic bath (Sonorex Digiplus, Bandelin GmbH & Co. KG, Berlin, Germany) for 10 
min. The RED Device inserts (8K MWCO) were fitted into the PTFE base plate, then 150 
µL of samples was placed into the donor chambers, while 300 µL of PBS (pH 5.6) was 
added to the acceptor chambers. Thereafter, the RED unit was covered with a sealing tape 
and incubated above gelling temperature (37 °C) on an orbital shaker (at 350 rpm) for 4 h. 
50 µL aliquots were withdrawn from the acceptor chamber at 5, 15, 30, 60, 120 and 240 
min time points and immediately replaced with the same amount of fresh medium. 50 µL 
of acetonitrile was added to the withdrawn samples and the MEL content was determined 
using HPLC. Five parallel measurements were performed. 
2.4.5. High Performance Liquid Chromatography (HPLC) 
The determination of MEL concentration was performed with an Agilent 1260 HPLC 
(Agilent Technologies, Santa Clara, CA, USA). A Kinetex® C18 column (5 µm, 150 mm × 
4.6 mm (Phenomenex, Torrance, CA, USA)) was used as stationary phase. The mobile 
phases consisted of 0.065 M KH2PO4 aqueous solution adjusted to pH = 2.8 with phos-
phoric acid (A), and methanol (B). A linear gradient from 50–50% to 25–75% (A-B eluent) 
was applied from 0 to 14 min. Then, from 14 to 20 min the phase composition was set back 
to 50%–50% A-B. Separation was performed at 30 °C with 1 mL/min flow rate. 10 µL of 
the samples was injected to determine the MEL’s concentration at 355 ± 4 nm using the 
UV-VIS diode array detector. Data were evaluated using ChemStation B.04.03. Software 
(Agilent Technologies, Santa Clara, CA, USA). The retention time of MEL was observed 
at 14.34 min. The regression coefficient (R2) of the calibration curve was 0.999 in the con-
centration range 1–200 µg/mL. The determined limits of detection (LOD) and quantifica-
tion (LOQ) of MEL were 16 ppm and 49 ppm, respectively. 
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2.4.6. In Vitro BBB Permeability Assay 
Parallel artificial membrane permeability assay (PAMPA) was used to determine the 
brain specific effective permeability of MEL from the reference suspension and the MEL-
HAS-P407 formulations [25]. The filter donor plate (Multiscreen™-IP, MAIPN4510, pore 
size 0.45 µm; Millipore, Merck Ltd., Budapest, Hungary) was coated with 5 µL of lipid 
solution containing 16 mg brain polar lipid extract (porcine) and 8 mg cholesterol dis-
solved in 600 µL dodecane. The Acceptor Plate (MSSACCEPTOR; Millipore, Merck Ltd., 
Budapest, Hungary) was filled with 300 µL of a PBS solution of pH 7.4. 150–150 µL of the 
formulation and the reference solutions were applied on the membrane of the donor plate. 
Then, this was covered with a plate lid in order to decrease the possible evaporation of 
the solvent. This sandwich system was incubated at 37 °C for 4 h (Heidolph Titramax 1000, 
Heidolph Instruments, Schwabach, Germany). The concentration of MEL permeated in 
the acceptor plate was determined using HPLC. The effective permeability and membrane 
retention of drugs were calculated using the following equation [25]: 𝑃  (cm s⁄ ) = − 2.303 ∙ 𝑉𝐴(𝑡 − 𝜏 ) ∙ log [1 − 𝑐 (𝑡)𝑆 ] (3)
where Pe is the effective permeability coefficient (cm/s), A is the filter area (0.24 cm2), VA is 
the volume of the acceptor phase (0.3 mL), t is the incubation time (s), τSS is the time to 
reach the steady state (s), cA(t) is the concentration of the compound in the acceptor phase 
at time point t (mol/mL), and S (mol/mL) is the solubility of MEL in the donor phase. The 
latter was determined after centrifugation (at 12000 rpm, 15 min, Eppendorf Centrifuge 
5804 R) in Microcon Centrifugal Filter Devices (30,000 MWCO) and 50-times dilution of 
the formulations, using the same HPLC system. The flux of samples was calculated using 
the following equation [26]: 𝐹𝑙𝑢𝑥 (mol cm ∙ s)⁄ = 𝑃 ∙ 𝑆 (4)
2.5. Cell Line Studies with Optimized Formulation 
2.5.1. Cell Cultures 
Human RPMI 2650 (ATCC cat. no. CCL 30) nasal epithelial cells were grown in Dul-
becco’s Modified Eagle’s Medium (DMEM, Gibco, Life Technologies, Gaithersburg, MD, 
USA) supplemented with 10% v/v fetal bovine serum (FBS, Pan-Biotech GmbH, Aiden-
bach, Germany) and 50 µg/mL gentamicin in a humidified 37 °C incubator with 5% CO2. 
The surfaces were coated with 0.05% rat tail collagen in sterile distilled water before cell 
seeding in culture dishes and the medium was changed every 2 days. When RPMI 2650 
cells reached approximately 80%–90% confluence in the dish, they were trypsinized with 
0.05% trypsin-0.02% EDTA solution. One day before the experiment, retinoic acid (10 µM) 
and hydrocortisone (500 nM) were added to the cells to form a tighter barrier [27]. 
For permeability measurements epithelial cells were co-cultured with human vascu-
lar endothelial cells [28,29] to create a more physiological barrier, representing both the 
nasal epithelium and the submucosal vascular endothelium. The endothelial cells were 
grown in endothelial culture medium (ECM-NG, Sciencell Research Laboratories, Carls-
bad, CA, USA) supplemented with 5% FBS, 1% endothelial growth supplement (ECGS, 
Sciencell Research Laboratories, Carlsbad, CA, USA) and 0.5% gentamicin on 0.2% gela-
tin-coated culture dishes (10 cm). For the permeability experiments, cells were used at 
passage 8. 
2.5.2. Cell Viability Measurements 
Real-time cell electronic sensing is a non-invasive, label-free, impedance-based tech-
nique to quantify the kinetics of proliferation and viability of adherent cells. Our group 
has successfully used this method to study cell damage and/or protection in living cells 
[30,31]. The RTCA-SP instrument (ACEA Biosciences, San Diego, CA, USA) monitored 
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the impedance of cell layers every 10 min. Cell index was defined as Rn-Rb at each time 
point of measurement, where Rn is the cell-electrode impedance of the well when it con-
tains cells, and Rb is the background impedance of the well with the medium alone. Cell 
index values reflect cell number and viability. 
The 96-well E-plates with integrated gold electrodes (E-plate 96, ACEA Biosciences, 
USA) were coated with 0.2% gelatin and incubated for 20 min in the incubator. Then gel-
atin was removed, and culture medium (50 µL) was added to each well for background 
readings. RPMI 2650 cell suspension was dispensed at the density of 2 × 104 cells/well in 
50 µL volume and the plate was kept in a humidified incubator with 5% CO2 at 37 °C. 
When cells reached a steady growth phase, they were treated with the nano-formulations 
and their components. 
2.5.3. Permeability Study on the Co-Cultured Model 
The tightness of the BBB co-culture model was verified by transepithelial electric re-
sistance (TEER) measurement, which reflects the tightness of cell layers of biological bar-
riers. TEER was measured by an EVOM volt-ohm meter (World Precision Instruments, 
Sarasota, FL, USA) combined with STX-2 electrodes, and it was expressed relative to the 
surface area of the monolayers as Ω × cm2. TEER of coated, but cell-free, filters were sub-
tracted from measured TEER values. Cells were treated with the nano-formulations when 
the cell layer reached steady TEER values. 
For the permeability studies we used a co-culture model, in which RPMI 2650 cells 
were cultured together with endothelial cells on inserts of a 12-well trans-well system 
(Transwell, polycarbonate membrane, 3 µm pore size, 1.12 cm2, Corning Costar Co., Low-
ell, MA, USA) for 5 days. In this model, endothelial cells were seeded (1 × 105 cells/cm2) to 
the bottom side of culture inserts coated with Matrigel (growth factor reduced, BD Biosci-
ences, San Jose, CA, USA) and nasal epithelial cells were passaged (2 × 105 cells/cm2) to 
the upper side of the membranes coated with rat tail collagen. 
During the permeability experiments, the inserts were placed on 12-well plates con-
taining 1.5 mL Ringer-HEPES buffer in the acceptor (lower/basal) compartments. In the 
donor (upper/apical) compartments, the culture medium was changed and 0.5 mL buffer 
containing different formulations and meloxicam as reference were added. To avoid an 
unstirred water layer effect, the plates were kept on a horizontal shaker (120 rpm) during 
the assay in a humidified incubator with 5% CO2 at 37 °C for 1 h. After incubation, samples 
were collected from the donor and acceptor compartments and the meloxicam concentra-
tion was measured by HPLC. 
To test the function of our co-culture model, the flux of permeability marker mole-
cules FITC-labeled dextran (FD10, Mw: 10 kDa) and Evans blue labeled albumin (EBA; 
MW: 67.5 kDa) was determined across the cell layers [31]. In the donor compartments of 
the inserts, 0.5 mL buffer containing FD10 (100 µg/mL) and EBA (167.5 µg/mL Evans blue 
dye and 10 mg/mL bovine serum albumin) was added and 12-well plates were placed on 
a horizontal shaker (120 rpm) for 30 min. After treatments, samples from the lower com-
partments were collected and the markers were measured with a fluorescence multi-well 
plate reader (Fluostar Optima, BMG Labtech, Ortenberg, Germany; FITC: excitation 
wavelength: 485 nm, emission wavelength: 520 nm; Evans-blue labeled albumin: excita-
tion wavelength: 584 nm, emission wavelength: 680 nm). 
The apparent permeability coefficients (Papp) were calculated as described previously 
[31] by the following equation: 𝑃 (cm s) = ∆[𝐶] × 𝑉𝐴 × [𝐶] × ∆𝑡 (5)
Briefly, Papp was calculated from the concentration difference of the tracer in the ac-
ceptor compartment (Δ[C]A) after 60 min, initial donor compartments’ concentration 
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([C]D), VA is the volume of the acceptor compartment (1.5 mL) and A is the surface area 
available for permeability (1.1 cm2). 
2.5.4. Treatments of Cultured Cells 
For cell viability measurements, 10, 30 and 100 times dilutions from optimized MEL-
HSA P407 formulation (14% w/w P407), 2 mg/mL meloxicam, 3 mg/mL Tween 80 and 160 
mg/mL P407 solutions were prepared in cell culture medium. For permeability measure-
ments, 2 mg/mL meloxicam and 10× times dilution of MEL-HSA-P407 were prepared in 
Ringer-HEPES buffer and added to the donor compartments. 
2.5.5. Immunohistochemistry 
To evaluate morphological changes in RPMI 2650 cells caused by the MEL-HAS-P407 
formulation and MEL, immunostaining for junctional proteins zonula occludens protein-
1 (ZO-1) and β-catenin was made. After the permeability experiments, cells on culture 
inserts were washed with phosphate buffer (PBS) and fixed with ice cold methanol–ace-
tone (1:1) solution for 2 min then washed with PBS 3 times. The nonspecific binding sites 
were blocked with 3% bovine serum albumin in PBS. Primary antibodies rabbit anti-ZO-
1 (AB_138452, 1:400; Life Technologies, Carlsbad, CA, USA) and rabbit anti-β-catenin 
(AB_476831, 1:400) were applied as overnight treatment at 4 °C. Incubation with anti-rab-
bit IgG Cy3 conjugated (AB_258792, 1:400) secondary antibodies lasted for 1 h and 
Hoechst dye 33342 was used to stain cell nuclei. After mounting the samples (Fluoro-
mount-G; Southern Biotech, Birmingham, AL, USA) staining was visualized by Leica TCS 
SP5 confocal laser scanning microscope (Leica Microsystems GmbH, Wetzlar, Germany). 
2.6. Statistical Analysis 
All data presented are means ± SD. In the case of mucoadhesive study, an unpaired 
t-test was applied. The values in the cell line studies were compared using the analysis of 
variance followed by Dunett or Bonferroni tests using GraphPad Prism 5.0 software 
(GraphPad Software Inc., San Diego, CA, USA). Changes were considered statistically sig-
nificant at p < 0.05. The significance of differences of RED and PAMPA data was calculated 
with one-way ANOVA with post hoc test (Tukey’s multiple comparisons test, α = 0.05). 
3. Results 
3.1. Comparative Risk Assessment of MEL-HSA and MEL-HSA-P407 
In addition to CQAs, well-defined goals must be set for the product to fit the nose-
to-brain route of administration. This route has many obstacles and challenges to over-
come, starting from the formulation process and the patient’s administration until the de-
veloped effect in the central nervous system. Due to the physiological and chemical vari-
ety through this pathway, a number of formulation aspects must be taken into considera-
tion ensuring the desired product quality and performance. This is determined by the 
QTPP of the product, the elements of which can be seen in Table 1. 
Table 1. QTPP elements of the nose-to-brain applicable HSA nanoparticle- and poloxamer-based in situ thermogelling system. 
QTPP Element Target 
Carrier integrity Nanosized particle size and distribution with uniform API content after gelation at gelation temperature. 
Drug release in the nasal cavity The formulation should release more MEL in the dissolu-tion medium compared to initial MEL at pH 5.6.  
Mucoadhesive properties The mucoadhesive force and work should be high enough to meet the requirements of the nasal delivery. 
Residence time on nasal mucosa Increased residence time compared to non-gel formula-tions. 
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Nasal epithelial cellular uptake 
The formulation should have higher permeability on nasal 
epithelial cells without damaging the cells forming the na-
sal barrier compared to raw MEL. 
Transport in the central nervous system 
The flux and permeability value of the gel formulation 
should be increased across BBB lipids compared to initial 
MEL 
The next step was to assign risk relations to MEL-HSA and MEL-HSA-P407 formu-
lations which were first prepared by interdependence rating on a three-level scale. Quan-
tifying these risks was interpreted using severity scores which were compared to each 
other. The tables of the interdependence rating and the severity scores are shown in Figure 
2. 
 
Figure 2. Interdependence rating amongst QTPPs (A), CQAs (C) and MEL-HSA, MEL-HSA-P407 formulations with the 
corresponding severity scores for QTPPs (B) and CQAs (D). Abbreviations: H: high, L: low, M: medium. 
Based on the calculated severity scores, it can be claimed that, by incorporating HSA 
nanoparticles as a part of an in situ thermo-gelling system, the severity of risk can be 
heavily reduced. As desired for the nose-to-brain pathway, in theory, with increased 
muco-adhesion properties, an increased residence time can be observed. The particle char-
acteristics are always of paramount importance and cannot be left out of the design space 
development. These parameters are closely related to the dissolution and absorption pro-
file of the nanocarrier. The reduction in the added-up severity score means that the prod-
uct quality can be improved and is the reason for the continuous manufacturing improve-
ment. With optimal P407 concentration, the increased residence time and muco-adhesiv-
ity along with the penetration-enhancement also contribute to the possibly increased drug 
release and permeability. However, individual risks must be investigated, as seen from 
the structure of this article. The risk of decrease in permeability due to the more structured 
gel system, with less API exposed to the dissolution media per time, is always there, which 
is why it is of the utmost importance and can be characterized as a high-risk relation. This 
possible unbeneficial risk can be countered by the improved residence behavior in the 
nasal cavity, providing the pharmacokinetics to an adequate extent. P407 itself has also a 
solubilizing effect which also opposes some of the unbeneficial possibilities. The determi-
nation of gelling properties also helps to evaluate the success of the development, so these 
factors are also investigated; however, this cannot be part of a comparative risk assess-
ment, as MEL-HSA nanoparticles themselves do not contain any gelling material. 
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3.2. Optimization of P407 Concentration in the Formulation 
3.2.1. Investigation of In Situ Thermo-gelling Properties 
During the optimization process, the effect of the P407 concentration on the gelation 
and rheological properties was analyzed. In the first part of our rheological investigation, 
the effect of the P407 concentration on the lower critical solution temperature (LCST) was 
measured. LCST was defined as the temperature at the crossover point of the storage 
modulus (G’) and loss modulus (G”), and primary data can be seen in Figure S1. Based on 
our results, we can conclude that a minimum of 13% w/w P407 concentration is needed 
for gelling at body temperature (Figure 3A). However, considering possible dilution in 
vivo, it is preferable to use a slightly higher concentration (at least 14% w/w or above). 
 
Figure 3. Effect of the P407 concentration on the gelling temperature (A), gelling time at 37 °C (B), and gel strength (C). 
Data is presented as means ± SD, n = 5. 
The gelling time significantly affects the bioavailability of the nasal preparation. If 
gelation is too slow, the mucosal concentration of the product is significantly reduced due 
to the elimination mechanisms, and dilution with a liquid layer covering the mucosa pre-
vents subsequent gelation. On the other hand, too fast a gelation can make it difficult to 
distribute the composition on the mucosa, therefore a reduced absorption surface can be 
expected. It can be clearly seen from our results that in case of 12–13% w/w P407 gelation 
time was too slow (6–7 min), but with the increasing polymer concentration (14–16% w/w) 
gel formation occurs within 2–3 min at 37 °C (Figure 3B), which seems to be optimal for 
nasal application. 
The rheological properties of gels at body temperature may also affect the bioavaila-
bility of the formulations. The stronger the gel structure, the more resistant it is against 
the mucosal elimination mechanisms. The nasal mucosa is characterized by the phenom-
enon of mucociliary clearance caused by the beating of the cilia. The effect of ciliary beat-
ing can usually be simulated by oscillatory rheological measurements at low oscillation 
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frequency [32]. In our case, we compared our formulations at the angular frequency of 1 
rad/s using frequency sweep tests. 
As can be seen in Figure 3C an elastic characteristic can be measured with only higher 
P407 concentrations, i.e., only samples containing 15–16% w/w P407 can be characterized 
with considerable elasticity at body temperature. Although gelation begins at body tem-
perature in the case of the 13–14% w/w systems, this results in only a very weak gel struc-
ture, which may not hinder drug release. As was also described in the literature [33], the 
poloxamer forms weak gels. 
3.2.2. Muco-adhesion Measurement 
Gelling at body temperature results in the micellar arrangement of P407 molecules, 
which may affect the muco-adhesiveness of the formulation. During the tensile test, the 
contact of the two surfaces can generate the change in the gel structure and the formation 
of the mucoadhesive interaction simultaneously. As a result of the two processes, we can 
observe high variability in the adhesive work and force values. 
In the case of our systems, adhesive forces of about 1000 mN were measured in al-
most all cases (Figure 4A), and it was found that the mucoadhesive force did not change 
remarkably with increasing P407 concentration. Only a slightly increasing tendency can 
be observed at higher polymer concentration (1100 mN). This can mean that the number 
of functional groups forming mucoadhesive bonds at the interface slightly increases. 
Comparing the muco-adhesivity of the in situ gelling systems with that of the NaHA, we 
can see a higher adhesive force value in the case of NaHA, but the difference cannot be 
considered as significant (p > 0.05 in each cases). 
 
Figure 4. Adhesive force (A) and adhesive work (B) of the compositions in various P407 concentrations. Data is presented 
as means ± SD, n = 5. 
In contrast, there is a slight increase in mucoadhesive work, and higher values of 
adhesive work can be measured in those compositions (14–16% w/w P407) where a gel 
structure is already formed at near body temperature (Figure 4B). In this case, with the 
formation of the gel structure, the formation of mucoadhesive physical bonds is more sig-
nificant. Comparing the formulated systems with the reference mucoadhesive, we could 
not detect significant differences (p > 0.05 in each cases), which could be the result of the 
large SD. 
3.2.3. Characterization of Carrier Systems 
Nanoparticle properties such as particle size, PdI, zeta potential, encapsulation effi-
cacy, loading capacity, pH and osmolality are key parameters for characterization of the 
therapeutic applicability of nasal formulations. These nasal administration-related param-
eters of the P407-containing formulation in different concentrations are presented in Table 
2. 
Pharmaceutics 2021, 13, 646 12 of 22 
 
 






25 °C 35 °C 









MEL-HSA-P12% 12 172 ± 2 0.189 ± 0.02 180.7 ± 3 0.193 ± 0.03 −9.4 ± 0.7 82.34 ± 0.12 1.26 ± 0.01 5.85 ± 0.08 200 ± 2 
MEL-HSA-P13% 13 175 ± 2 0.211 ± 0.01 188.7 ± 2 0.282 ± 0.02 −8.5 ± 0.5 82.01 ± 0.19 1.17 ± 0.02 5.81 ± 0.04 220 ± 3 
MEL-HSA-P14% 14 176 ± 3 0.205 ± 0.02 193.7 ± 2 0.211 ± 0.02 −7.9 ± 0.3 81.64 ± 0.21 1.09 ± 0.02 5.61 ± 0.05 242 ± 3 
MEL-HSA-P15% 15 182 ± 3 0.234 ± 0.03 262.4 ± 3 0.306 ± 0.03 −7.1 ± 0.4 81.19 ± 0.23 1.03 ± 0.01 5.60 ± 0.02 278 ± 2 
MEL-HSA-P16% 16 231 ± 3 0.268 ± 0.02 304.3 ± 5 0.328 ± 0.04 −7.0 ± 0.2 79.46 ± 0.24 0.97 ± 0.01 5.52 ± 0.07 311 ± 4 
The Z-average, PdI and zeta potential value of formulations was measured both in 
sol and gel state. Formulations containing 12–14% w/w P407 meet the requirements of in-
tranasally administered nanoparticles (<200 nm) even after thermo-gelling, but in case of 
15–16% w/w P407 these parameters are out of the acceptance criteria. Moreover, the Z-
average (in the range of 180–193 nm) of gel embedded MEL-HSA nanoparticle suggests 
increased drug release. The narrow PdI (from 0.193 to 0.328) indicates monodispersed size 
distribution, which ensures the homogeneity of nanoparticles in the gel structure. The 
distribution of FITC labelled MEL-HSA nanoparticles was visualized in the gel structure 
using fluorescent microscopy (Figure 5). 
 
Figure 5. FITC-labelled MEL-HSA nanoparticles and their distribution in gel structure containing 
various concentrations of P407 at 60× magnification. 
The fluorescent, microscopic images prove the homogenous distribution of MEL-
HSA nanoparticles and narrow PdI, and gelling of the formulations did not show an ag-
gregation tendency of the nanoparticles. There was no remarkable difference in zeta po-
tential (between −9.4 and −7.0 mV) of formulations and these values indicate that repul-
sion of nanoparticles is not significant enough to avoid aggregation in sol form. Both en-
capsulation efficacy and loading capacity of formulations were slightly decreased with 
increasing P407 concentration, but even so this difference was not remarkable, therefore 
from this point of view each formulation can be suitable for application. The osmolality 
of formulations containing 12–15% w/w P407 was hypotonic (200–278 mOsmol/L), which 
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predicts enhanced drug absorption, offsetting the retention of gel structure. In case of 16% 
w/w P407 the formulation was hypertonic (311 mOsmol/L), which can result in significant 
dehydration of nasal mucosa; therefore, from a therapeutic point of view the application 
of MEL-HSA-P16% is not recommended. 
3.2.4. In Vitro Dissolution Profiles (RED) 
The drug release kinetic of in situ gelling formulations is a critical part of rational 
drug design as it is a major determinant of the efficacy of delivery of the carrier in vivo 
and the subsequent release of the free drug. The in vitro release profile reveals important 
information on the structure and behavior of the formulation, on possible interactions be-
tween the drug and carrier composition, and on their influence on the rate and mechanism 
of drug release. The dialysis-based release method is a well-established and useful tech-
nique to study in vitro release from nano-particulate delivery systems. RED device was 
developed in order to reduce the time to equilibrium, and to provide results faster than 
other dialysis methods [34]. In this system, MEL conjugated HSA nanoparticles are phys-
ically separated from the acceptor media by a dialysis membrane with 8 kDa cutoff which 
allows only the passive diffusion of free MEL into the acceptor media. The time-depend-
ent in vitro release profiles of MEL and formulations were determined with RED (Figure 
6). 
 
Figure 6. In vitro dissolution profiles of MEL-HSA-P407 formulations in comparison to starting 
MEL. Data is presented as means ± SD, n = 5. 
The in vitro dissolution profiles of MEL-HSA-P407 and starting MEL were investi-
gated in intranasal conditions (pH = 5.6). Due to the weak acidic character of MEL (pKa = 
3.43 [26]) it can be found in fully ionized form in dissolution medium ( 2 < ∆𝑝𝐻 =|𝑝𝐻 − 𝑝𝐾 |), although the dissolution profile of pure MEL shows only a slight increase. In 
the case of formulations, a significantly increased dissolution was observed compared to 
pure MEL (**, p < 0.01), due to the nano size and increased specific surface area of MEL-
HSA nanoparticles and the solubilizing effect of Tween. The dissolution profiles of the 
formulations clearly demonstrate the effect of polymer on drug release. When increasing 
the concentration of P407 in the formulation, the dissolution of MEL was slower, which 
can be explained by the hindered liberation of MEL through the more viscous gel struc-
ture. Interestingly, formulations containing P407 in a lower concentration (12–13% w/w) 
followed Hixon-Crowell kinetics, which is presumably the less effective anti-aggregation 
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effect due to the reduced polymer concentration; but in higher concentrations (14–16% 
w/w) zero-order kinetics dominated (Table 3) [35]. The best fit of kinetic data is presented 
in Figure S2. Similar types of effect of P407 gel on the release behavior of insulin [36], 
paclitaxel [37], ceftiofur [38] and recombinant hirudin [39] have also been observed, in 
which the mode of drug release followed zero order. 
Table 3. Obtained kinetic parameters of in situ thermogelling nasal formulations. 










k0 (µg min−1) 0.342 0.293 0.368 0.31 0.258 
R2 0.9265 0.9251 0.9904 0.9968 0.9976 
t0.5 (min) 342.31 292.61 357.98 310.02 257.76 
First order 
k1 × 10−3 (min−1) 1.487 1.126 1.254 1.092 0.974 
R2 0.9584 0.9586 0.9927 0.9723 0.9972 
t0.5 (min) 466.15 615.43 552.71 634.49 711.49 
Higuchi model 
kH (µg min−1/2) 30.58 84.75 81.47 90.67 62.43 
R2 0.7954 0.7855 0.8708 0.8883 0.8684 
t0.5 (min) 427.58 718.23 663.67 822.44 389.75 
Korshmeyer-
Peppas model 
kK-P × 10−2 (min−n) 9.427 5.684 2.998 3.118 3.292 
n 1.05 1.11 1.23 1.21 1.17 
R2 0.6105 0.5516 0.7221 0.8396 0.7453 
t0.5 (min) 1043.99 1618.39 2047.18 1740.98 1848.54 
Hixon-Crowell 
model 
kH-C (µg 1/3 min−1) 0.01 0.0046 0.0062 0.0043 0.0029 
R2 0.9838 0.987 0.9877 0.9863 0.9974 
t0.5 (min) 1610.35 2055.94 1950.68 2178.88 2466.87 







Zero order Zero order Zero order 
3.2.5. In Vitro BBB Permeability 
In the case of nasal administration, it should be taken into account that a fraction of 
the drug can be absorbed into the systemic circulation, from where it can only reach the 
brain if it is able to pass the BBB. It has been reported that NSAIDs have low disposition 
in the CNS via systemic circulation [40]. To investigate this formulation ability, the brain 
lipid-specific PAMPA permeability assay (PAMPA-BBB) is suitable. The PAMPA-BBB re-
sults of MEL-HSA formulations containing P407 in various concentrations in comparison 
to pure MEL are shown in Figure 7. Each P407 containing formulation showed signifi-
cantly higher flux compared to pure MEL (**, p < 0.01), which can be explained by the 
enhanced solubility of MEL due to the solubilizing effect of HSA and P407. Moreover, in 
the case of 14% w/w P407 the flux was by far the highest among all of the formulations (**, 
p < 0.01). This phenomenon can be explained by the adequate balance of the resultant 
effect of nanoparticle characteristics and drug release kinetics. Formulations containing 
P407 in lower concentrations (12–13%) followed Hixon-Crowell kinetics, assuming a 
lower sustained saturation of drug, whereas the formulations containing P407 in higher 
concentrations (14–16%) followed zero order kinetics, indicating a faster drug release. 
From these zero-order kinetics, the following compositions MEL-HSA-P14% had the high-
est rate constant (0.368 µg min−1), which can be rationalized as the smaller Z-average re-
sulting in a higher specific surface area; therefore, the higher dissolution rate ensures an 
increased gradient between donor and acceptor phases promoting permeation. In case of 
lower polymer concentration (12–13%) the effect of different drug release kinetics is neg-
ligible, as the remarkable Z-average difference of gel-embedded nanoparticles has a dom-
inant influence on concentration in the donor phase. 




Figure 7. Fluxes in PAMPA-BBB permeability study of MEL-HSA-P407 formulations compared to 
starting MEL. Data is presented as means ± SD, n = 6. 
Summing up, and based on the rheological, muco-adhesion, drug release and per-
meability studies, the 14% w/w P407 containing formulation (MEL-HSA-P14%) was con-
sidered as the optimized formulation from a therapeutic point of view. MEL-HSA-P14% 
forms a weak but mucoadhesive gel structure at 32 °C within 3 min which allows en-
hanced permeability of MEL through blood–brain barrier-specific lipids. Therefore, in the 
cell line studies, we decided to investigate that composition further. 
3.3. Evaluation of Cell Line Studies 
3.3.1. Cell Viability Assay 
Impedance measurement as a sensitive method to detect alteration in cellular viabil-
ity did not show cell damage after a 1-h treatment with MEL-HSA-P14% formulation or 
its components (Figure 8). As a comparison, the reference compound Triton X-100 deter-
gent caused cell death, as reflected by the decrease in impedance. 




Figure 8. Cell viability of RPMI 2650nasal epithelial cells after a 1-h treatment with MEL, MEL-
HSA-P14% formulation, or with their components, measured by impedance. The values are pre-
sented as a percentage of the control group (means ± SD, n = 6–12). Statistical analysis: ANOVA 
and Dunett’s test. *** p < 0.01, compared to the control group. TX-100, Triton X-100 detergent. 
3.3.2. MEL Permeability across the Culture Model of the Nasal Mucosa Barrier 
The permeability of MEL was tested on the nasal epithelial and vascular endothelial 
cell co-culture model (Figure 9). After a 1-h treatment MEL in MEL-HSA-P14% showed 
significantly higher (four-fold) Papp value compared with MEL suspension (MEL) (Figure 
9). This result is in agreement with our previous finding using nanonized MEL in nasal 
formulation in the human RPMI 2650 nasal epithelial cell model [27] and also with results 
of PAMPA-BBB in the present study. 
 
Figure 9. Permeability of MEL (2 mg/mL in all samples) and MEL-HSA-P14% nano-formulation 
across a co-culture model of human RPMI 2650 nasal epithelial cells and vascular endothelial cells 
(1-h assay). Values are presented as means ± SD, n = 3. *** p < 0.001 significantly different from 
MEL control. 
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We found adequate TEER and low permeability values for paracellular markers in-
dicating a good barrier property of the nasal mucosa co-culture model (Figure 10). Both 
the TEER and Papp values were better than in the mono-culture model we described earlier 
[27]. The TEER values of the co-culture model remained at the level of the control group 
after a 1-h treatment with MEL-HSA-P14%, indicating that it did not damage the barrier 
function of the model (Figure 10A). MEL increased TEER and both treatments decreased 
Papp values for the two hydrophilic paracellular marker molecules, dextran and albumin 
(Figure 10B). This result suggests that the anti-inflammatory MEL may have a beneficial 
effect on the nasal barrier either alone or in formulation. 
 
Figure 10. Transepithelial electrical resistance (TEER) of the co-culture model after a 1-h treatment with MEL and MEL-
HSA-P14% (A). Values for paracellular permeability markers fluorescein-labeled dextran (FD10) and Evans blue-labeled 
albumin (EBA) after a 1-h treatment with MEL and the nano-formulation (B). Values are presented as means ± SD, n = 3. 
C: control; MEL; MEL-HSA-P14%. * p < 0.05; *** p < 0.001 significantly different from control. 
3.3.3. Immunohistochemistry 
The staining pattern of the junctional linker proteins ZO-1 and β-catenin on human 
RPMI 2650 nasal epithelial cells in the co-culture model was typical for epithelial barriers. 
The cell shape was cobblestone, and the junctional proteins were visible in a belt-like man-
ner at the cell borders (Figure 11), in concordance with our previous results [27]. We found 
no change in the staining pattern after the 1-h treatments as compared to the control group 
(Figure 11) indicating that the formulation did not damage the barrier model. 




Figure 11. Immunostaining for junctional linker proteins ZO-1 and β-catenin on human RPMI 
2650 nasal epithelial cell layers following a 1-h treatment with MEL and MEL-HSA-P14%. The 
control group (C) received only medium. Red: junctional proteins; blue: cell nuclei. Scale bar: 20 
µm. 
4. Discussion 
A series of NSAIDs, including MEL, show significant potential in Alzheimer’s dis-
ease although their administration through conventional routes results in low deposition 
in the CNS due to severe elimination mechanisms and low capability of by-passing the 
BBB. Therefore, the application of a suitable nano carrier can be promising in increasing, 
their bioavailability [40]. HSA, as a versatile, biodegradable nano-carrier is an auspicious 
tool for intranasal delivery of NSAIDs, as several studies have already proved the suc-
cessful nose-to-brain delivery of candidates like flurbiprofen [41] or MEL [13] itself. Alt-
hough the exact pathway of HSA through nose-to-brain delivery is still not clearly demon-
strated, experimental results showed that isotope labelled albumin could reach the brain 
after nasal administration [42]. 
The intranasal applicability of MEL-HSA nanoparticles is limited by mucociliary 
clearance, therefore application of the in situ gelling mucoadhesive polymer P407 can be 
advantageous, since the above mentioned LCST, PPO chains become less soluble resulting 
in micelle formation and entanglements followed by gelation of the sol form [43,44]. Sev-
eral studies have demonstrated that poloxamer-based in situ gelling formulations have 
been successfully applied in numerous therapeutic fields especially among neurological 
diseases such as in the therapy of migraine [45], Parkinson’s syndrome [46], Alzheimer’s 
disease [47–49] and depression [50]. The basic ingredient of the therapeutic effectiveness 
of in situ thermo-gelling nasal formulations is their advantageous nature, which besides 
improving the pharmacokinetic profile of the administered drug also increases patients’ 
compliance [51]. Their sol form allows accurate dosing e.g., by the use of a metered dose 
nasal actuator system and after gelling, post-nasal drip into the throat can be reduced, 
therefore minimizing any undesired taste problem and loss of drug from the nasal cavity. 
The gel form ensures increased residence time of the formulation on nasal mucosa, exhib-
iting sustained release and supporting drug absorption. Moreover, gels can be used along-
side demulcents or emollients which may not be suitable for solutions, suspensions or 
even powder dosage forms, in order to reduce the irritation potential. 
Besides these mucoadhesive properties, particle characteristics play an important 
role in the applicability of formulations through the nasal administration route. It has been 
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reported that nanoparticles with an average hydrodynamic diameter of 20–200 nm are the 
most suitable for nose-to-brain transport [52]. The PdI also plays a very important role in 
drug pharmacokinetics since a lower value indicates an enhanced probability of a more 
uniform absorption through the nasal mucosa, while a higher value may lead to pharma-
cokinetic irregularity and variability in the therapeutic outcome [53]. It is usually recom-
mended that the PdI should be below 0.5. The zeta potential, which is dependent on both 
the surface charge of the particles and the ionic strength of the medium used for particle 
dispersion, is recommended to have a slightly negative or even positive surface charge, 
as this enhances nasal absorption as the nasal mucosa itself is negatively charged. More-
over, increased encapsulation efficacy and drug loading of nanoparticles is required to 
ensure proper dosing restricted by lower administration volume, up to a maximum of 200 
µL. Our albumin nanoparticle gelling formulations containing 12–14% w/w P407 met these 
requirements and became suitable for intranasal administration after thermo-gelling; 
moreover, these parameters were more promising than in case of flurbiprofen-albumin 
nanoparticles, which were already successfully administered intranasally, directly to the 
brain, by Wong et al. [41]. 
Besides the particle characteristics of albumin nano-particles, the physiological prop-
erties of the nasal cavity should be also taken into account. The pH of the formulations 
was in the range of the human nasal mucosa’s physiologic pH range (4.62 to 7.00) sup-
porting normal ciliary function and reducing the chance of damaging the barrier integrity 
of the nasal epithelial cells [54]. In this slightly acidic environment, lysozyme, the natural 
antimicrobial agent in the nose, is effective in the prevention of the growth of pathogenic 
bacteria in the nasal passage; therefore, preservative agents are negligible, which is usu-
ally incompatible with the applied polymer. Nasal preparations are normally isotonic 
(about 290 mOsmol/L), which is also best tolerated, but sometimes a deviation from iso-
tonicity may be advantageous. Especially, hypotonic solutions can facilitate drug absorp-
tion through interfering with cilia movement [55]. Based on these perspectives, our opti-
mized formulation MEL-HSA-P14% met all the listed requirements, which suggests suit-
able therapeutic applicability, which can be corroborated with the experimental results of 
Giuliano et al., according to which prolonged delivery of the drug for up to 5 h from P407 
hydrogel was achieved via increasing the permeation profile of the compound, as meas-
ured through ex vivo porcine nasal mucosa [56–57]. 
5. Conclusions 
In summary we optimized an in situ thermo-gelling MEL-HSA-P407 formulation, 
which can be administered in liquid state into the nostril. Temperature dependent sol-gel 
transition on the mucosa, resulting in increased resistance against mucoliciary clearance, 
can estimate improved drug absorption. Based on rheological, muco-adhesion, drug re-
lease and permeability studies, MEL-HSA-P14% was considered as the optimized formu-
lation. Cell line studies showed no cell damage after a 1-h treatment with MEL-HSA-P14% 
on RPMI 2650 human endothelial cells; moreover, enhanced permeation (four-fold) of 
MEL from MEL-HSA-P14% was observed in comparison to MEL suspension. Overall, 
MEL-HSA-P14% is promising in terms of overcoming the challenges of nasal drug deliv-
ery by increasing resistance against mucociliary clearance, and therefore can improve na-
sal drug absorption. 
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